AMRX Q1 2021 Earnings — Amneal Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

AMRXAmneal Pharmaceuticals, Inc.

$4B

Q1 2021 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$493M-1.1% YoY

Gross Profit

$192M38.8% margin

Operating Income

$46M9.3% margin

Net Income

$7M1.4% margin

EPS (Diluted)

$0.04

QoQ Revenue Growth

-3.3%

Cash Flow

Operating Cash Flow

$148M

Free Cash Flow

$136M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$4.0B

Total Liabilities

$3.6B

Stockholders' Equity

$323M

Cash & Equivalents

$452M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$493M	$499M	-1.1%
Gross Profit	$192M	$183M	+4.4%
Operating Income	$46M	$58M	-20.6%
Net Income	$7M	$115M	-94.2%

Revenue Segments

Generics Segment

$313M63%

Amneal Specialty Pharma Segment

$96M19%

Av K A R E Segment

$85M17%